Details of the Drug Combinations

General Information of This Drug (ID: DMGLSPC)

Drug Name
Salicylhydroxamic acid   DMGLSPC
Synonyms
Salicylhydroxamic acid; N,2-Dihydroxybenzamide; 89-73-6; 2-Hydroxybenzohydroxamic acid; Salicylohydroxamic acid; SHAM; Salicylohydroximic acid; Benzamide, N,2-dihydroxy-; 2-Hydroxybenzhydroxamic acid; O-Hydroxybenzohydroxamic acid; SalicylhydroxaMicacid; SHA; 2,N-Dihydroxy-benzamide; NSC 5088; NSC 193440; Saliaylhydroxamic acid; UNII-8Q07182D0T; 2-hydroxybenzenecarbohydroxamic acid; Salicylic Hydroxamic Acid; EINECS 201-934-3; Salicylhydroxamic acid, 99%; MLS000069410; CHEMBL309339; CHEBI:45615; NSC5088
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
PF-04634817 + Salicylhydroxamic acid DCFG1WJ PF-04634817 Macular Edema, Diabetic [2]
Salicylhydroxamic acid + Aflibercept DC9QBQT Aflibercept Exudative Age-related Macular Degeneration [3]
Salicylhydroxamic acid + Aflibercept DCTMP0Y Aflibercept Neovascular Age-related Macular Degeneration [4]
------------------------------------------------------------------------------------

References

1 Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
2 ClinicalTrials.gov (NCT01994291) A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
3 ClinicalTrials.gov (NCT04200248) A Phase II Study of RBM-007 Alone and RBM-007 With Eylea in Subjects With Wet Age-related Macular Degeneration
4 ClinicalTrials.gov (NCT04684394) A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration